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Abstract: The aim is to review major clinical trials that have used megestrol acetate (MA) in 
the treatment of cachexia across several disease states. A review of general usage and potential 
side-effects are discussed. A theory that the newly approved nanocrystal formation of MA can 
better deliver this potent medication for treatment will also be reviewed.
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Introduction
Weight loss among elderly patients is a common clinical problem. For patients with 
more than 4% weight loss, 2-year survival rate is less than 72%, and 3-year survival 
rate is less than 65% (Wallace et al 1995; Wallace and Schwartz 1997).
This manuscript will summarize the results of our studies and discuss and review 
the general usage of megestrol acetate (MA) in the treatment of weight loss in cachectic 
elderly, cancer, and HIV patients.
Involuntary weight loss in the elderly is difﬁ  cult to treat. Roberts and colleagues 
(Roberts et al 1994, 1997; Roberts 1995, 2000) investigated the effects of aging on 
the mechanism of body energy regulation and thereby determined the causes of unex-
plained weight loss in older persons. They found that aging may be associated with 
a signiﬁ  cant impairment in the ability to control food intake following overeating or 
undereating. Overeating and undereating are part of the normal pattern of lifetime 
energy regulation. Hospitalization resulting in undereating can have a devastating 
effect on the frail elderly (Sullivan et al 1999). These frail elderly then are thrown into 
a downhill spiral. Any attempt to correct undereating and poor appetite may change 
the course of survival.
Studies in both cancer patients and HIV patients have shown that MA can improve 
appetite and help patients gain weight (Tchekmedyian et al 1987, 1991; Oster et al 
1994; Von Roenn 1994). MA is a synthetic derivative of a naturally occurring pro-
gestational agent, which is similar to progesterone. MA is well tolerated in patients 
with advanced malignant diseases and has a positive dose-response effect on appetite 
stimulation (Tchekmedyian et al 1987, 1991; Oster et al 1994). Loprinzi et al (1994) 
found the optimal dose in their study to be 800 mg/day. Loprinzi et al (1993) found 
that this was primarily non-ﬂ  uid weight. MA has also been shown to improve body 
weight, sense of appetite, and performance status in patients with hormone-insensitive 
cancers (Feliu and Gonzalez-Baron 1992). The FDA approved in 1994 the use of MA 
for the treatment of anorexia, cachexia, and/or an unexplained, signiﬁ  cant weight loss 
in patients with a diagnosis of acquired immunodeﬁ  ciency syndrome (AIDS). MA 
was ﬁ  rst produced in a tablet form, then in a concentrated oral suspension form, and 
most recently, in an oral suspension form developed using nanocrystal technology. International Journal of Nanomedicine 2006:1(4) 412
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Nanocrystal technology was designed speciﬁ  cally to optimize 
drug delivery and enhance the bioavailability of drugs that 
have poor solubility in water.
Mechanism of MA
The precise mechanism by which MA promotes weight gain 
is unclear. Proposed mechanisms and their potential side-
effects are summarized in Figure 1. Reported results show 
that MA may act both an progestational agent as well as an 
anti-inﬂ  ammatory/glucocorticoid agent (Bojar et al 1979; 
Kontula et al 1983; Loprinzi et al 1992a, 1992b; Pridjian 
et al 1987; Selman et al 1996, 1997; Chang 1998; Gomez 
et al 1998a, 1998b, 2002; Meacham et al 2003). Lapp et al 
(1995) have found, for example, that higher endogenous 
progesterone concentrations are common in late pregnancy, 
and those elevated concentrations result in decreased IL-6 
levels, which are 40%–50% of controls. It makes sense 
that progesterone plays an important role in improving 
nutritional status and decreasing localized inﬂ  ammation by 
down-regulation of IL-6 production during pregnancy. MA 
also has been found to decrease cytokine production during 
the treatment of malignancy (Barak et al 1998; Mantovani 
1997; Mantovani et al 1998a, 1998b).
Wiedemann et al (1998) found that MA dosages between 
160 and 480 mg activate progesterone receptors and lead to 
pituitary hormone secretion of a well-deﬁ  ned progesterone 
receptor ligand in a non-linear U-shape dose dependency. Our 
experience in randomized studies indicates that across both 
placebo and active treatment groups, there is a statistically 
signiﬁ  cant negative correlation between the levels of pro-
inﬂ  ammatory cytokines, such as IL-6 and TNF, and various 
nutritional parameters, body mass indices, improvement in 
QOL, and weight gain (Yeh et al 2000a, 2000b, 2001). These 
ﬁ  ndings seem to support a role for inﬂ  ammatory cytokines in 
the idiopathic cachexia syndrome of the elderly. MA binds 
to glucocorticoid receptors (Kontula et al 1983) in a possible 
dual agonist–antagonist fashion, acting as a weak agonist, 
but then serving as an antagonist in blocking the binding of 
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Figure 1 Summary of proposed megestrol acetate (MA) mechanism for weight gain and potential side-effects.
Abbreviations: CA, cancer; Con A, concanavalin A; HTN, hypertension; MA, megestrol acetate; Pha, phytohemagglutinin; PIC, pro-inﬂ  ammatory cytokine; RX: treatment; 
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more potent endogenous glucocorticoids (Kontula et al 1983; 
Mann et al 1997). Structural similarities between MA and 
glucocorticoids have been invoked to explain glucocorticoid-
like activity and increased peripheral resistance to insulin 
after treatment with the drug (van Veelen et al 1984, 1985; 
Loprinzi et al 1992b; Herkert et al 2001).
The dual action of MA may be the possible explanation 
for the unresolved inconsistencies of megestrol acetate’s 
neuroendocrine-progesterone effects and its potential 
reported side-effects such as hyperglycemia, hypoglycemia, 
venous thromboembolism, secondary adrenal suppression, 
and adrenal insufﬁ  ciency (Selman et al 1996, 1997; Koller 
et al 1999; Herkert et al 2001; Oberhoff 2001; McKone 
et al 2002; Bennett 2003; Kropsky et al 2003; Thomas 
2004). Reuben and colleagues reported that all patients 
had cortisol suppression after 9 weeks on MA (70% with 
MA>400mg/day) (Reuben et al 2005). The suppression 
of the adrenal axis was at the level of the hypothalamus/
pituitary (Kontula et al 1983). Effects on cortisol are 
reversed in 2–4 weeks once off MA (Meacham et al 2003). 
MA also inhibits CON-A and PHA stimulated T-cell 
proliferative response (Kontula et al 1983), making patients 
with long-term usage of MA vulnerable to infection and 
malignancy. Short-term (12 weeks) use of the drug appears 
to be safe (Yeh et al 2000b; Pascual Lopez et al 2004; 
Simmons et al 2004; Reuben et al 2005).
Review of clinical trials
MA appears to be one of the more potent appetite stimulants 
of currently used drugs (Loprinzi et al 1999; Mwamburi 
et al 2004; Jatoi et al 2002, 2004; Tomiska et al 2003). Jatoi 
found that eicosapentaenoic acid (EPA) supplement, either 
alone or in combination with MA, is no better than MA alone 
(Jatoi et al 2002, 2004). MA provided superior anorexia 
palliation among advanced cancer patients compared 
with dronabinol alone (Jatoi et al 2002), and combination 
therapy did not appear to confer additional beneﬁ  t (Jatoi 
et al 2002). Pascual Lopez et al (2004) did relevant database 
searches for randomized controlled trials of MA to treat 
anorexia–cachexia in patients with cancer, AIDS, or other 
conditions. Data were extracted by two independent review-
ers, and meta-analyses were performed where possible; 26 
studies were included (n=3887). Compared with placebo, 
MA increased appetite in oncology patients (Pascual Lopez 
et al 2004), led to weight gain (RR=1.88 [95% CI 1.43–2.47]) 
and improved quality of life (HRQOL) (RR=1.52 [95% CI 
1.00–2.30]). In AIDS patients, it increased weight (RR=2.16 
[95% CI 1.45–3.21]). There were no appreciable differences 
between lower (<800 mg/day) and higher (>800 mg/day) 
doses of MA (Pascual Lopez et al 2004). They found the 
main side-effect of MA was lower limb edema (RR=1.67 
[CI 1.22–2.28]) (Pascual Lopez et al 2004). Berenstein and 
Ortiz (2005) also found MA improved appetite and weight 
gain in patients with cancer in their Cochrane Database 
System Review.
MA usage, dosing, and duration
Our experience with MA has shown that its use in treating 
cachexia in the elderly improves quality of life and weight 
gain (Yeh et al 2000b, 2001).
We found that MA improved appetite (Yeh et al 2000b) 
and had a tendency to improve weight gain. Furthermore, 
it improves quality of life (Yeh et al 2000a, 2000b). During 
the study, reduction of pro-inﬂ  ammatory cytokine levels was 
associated with improved quality of life, as well as increased 
appetite, lean muscle mass, and overall weight (Yeh et al 
2000b, 2001).
Increasing prealbumin correlated with reduction in TNFR-
p55 and TNFR-p75 (Yeh et al 2000b, 2001). There was no 
difference in adverse effects between two groups (Yeh et al 
2000b). Increasing weight/fat free mass correlated with reduc-
tion in sIL-2r and TNFR-p75 (Yeh et al 2001). Improving 
appetite correlated with quality of life improvement, weight 
gain, and nutritional indicator changes (Yeh et al 2000a, 2000b, 
2001). Reduction in one pro-inﬂ  ammatory cytokine was highly 
correlated with reduction in the other cytokine levels (Yeh 
et al 2001). The factors that could predict survival among the 
subjects were higher prealbumin, albumin, and weight gain 
(Yeh et al 2000b, 2001, 2004). Elevated IL-6, CRP, TNFR-p55 
and TNFR-p75 were associated with decreased survival (Yeh 
et al 2000b, 2001, 2004). However, no signiﬁ  cant differences 
in survival were noted between the MA-treated and the placebo 
groups (p=0.72), as estimated by the Kaplan-Meier method 
(Yeh et al 2000a, 2000b, 2001, 2004).
In our experience, most patients had improved appetite by 
6 weeks with MA treatment, although the weight gain was not 
yet signiﬁ  cant at that time (Yeh et al 2001, 2000b). A course 
of treatment with MA for 12 weeks is probably enough to 
improve the appetite that will result in eventual weight gain. 
By 6 months, the MA group had signiﬁ  cant weight gain. 
Most of the treated patients gained weight, and there was a 
trend for this weight gain to be in the form of fat. Increased 
fat mass has been noted in patients with cancer and AIDS 
following treatment with MA (Von Roenn et al 1988; Loprinzi 
et al 1993; Von Roenn 1994; Von Roenn and Knopf 1996). 
Dulloo and colleagues (Dulloo et al 1997; Dulloo 1998, 1997) International Journal of Nanomedicine 2006:1(4) 414
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found that replenishment of fat stores was the initial event 
following feeding of volunteers previously subjected to 
semi starvation and reported that this observation could be 
generalized to recovery from other forms of refeeding after 
weight loss. They attributed the preferential gain in fat to 
reduced thermogenesis and changes in energy partitioning 
during recovery from starvation. The initial gain in fat mass 
was related to the pre-starvation fat mass (patients with a 
higher initial fat mass gained more fat during recovery). 
Gaining fat may be the ﬁ  rst step toward recovering from 
cachexia–starvation. No patients in this study had fat mass 
increases that were sufﬁ  cient to make them obese or to take 
them beyond the normal range for fat mass. Several studies 
reported that inclusion of resistance exercise training led to 
gains–maintenance in lean body mass and better functional 
improvement results (Strawford et al 1998, 1999).
Old formulation MA oral suspension (Megace® OS, 
Bristol-Myers Squibb, Princeton, NJ, USA) is best given 
at a dosage of 480–800 mg with a maximum daily dose of 
800mg and taken with meals (Pascual Lopez et al 2004; 
Berenstein and Ortiz 2005). Newer MA nanocrystal oral 
suspension (Megace® ES) employs a nanocrystal strategy 
that increases the surface area and, therefore, the absorption 
and bioavailability of the drug. It can be given at a dosage 
of 625mg (5mL) daily in the fed or unfed state.
Most patients treated with conventional MA suspension 
had improved appetite by 6 weeks, although weight gain was 
not yet signiﬁ  cant at that time. A course of treatment with 
MA for 12 weeks is probably enough to improve the appetite 
for eventual weight gain (Yeh et al 2000b). Lambert and 
co-workers found that despite signiﬁ  cant weight gain, MA 
appears to have an anti-anabolic effect on muscle size even 
when combined with testosterone replacement. Resistance 
exercise attenuated this reduction in muscle mass. When 
MA is combined with testosterone and resistance exercise, 
resistance exercise had an anabolic effect on muscle mass 
(Lambert et al 2002). Thus, patients should also receive 
strength and a local, muscular, endurance-training program 
to improve their functional status. If there is no improve-
ment in appetite by week eight, we suggest discontinuing 
the usage of MA because of the potential secondary adrenal 
suppression and adrenal insufﬁ  ciency.
Common clinical practice has been to stop MA without 
tapering the dose because of its long half-life and storage in 
adipose tissue (Loprinzi 1996; Loprinzi et al 1992a, 1992c). 
No untoward clinical sequelae have been seen in most patients 
(Tchekmedyian et al 1987, 1991; Oster et al 1994; Pascual 
Lopez et al 2004; Simmons et al 2004). The deposition of 
MA in fat stores may allow for a naturally occurring slow 
tapering of glucocorticoid activity after discontinuation of 
therapy. Patients who require more than 12 weeks of treat-
ment should have their morning free cortisol levels checked 
at 12 weeks and biweekly thereafter. A patient with adrenal 
suppression, ascertained by an abnormal adrenocorticotropic 
hormone (ACTH) stimulation test, but with no symptoms of 
adrenal insufﬁ  ciency, should be monitored for fever, nausea 
and vomiting, hypotension, dehydration, clouded sensorium, 
pain in the abdomen, joints, and muscles, hypoglycemia, 
and acidosis. Upon withdrawal of the drug, biochemical 
suppression of cortisol alone is not sufﬁ  cient to warrant 
adrenal hormone replacement therapy. This is because adrenal 
suppression is not equivalent to adrenal insufﬁ  ciency.
If, on the other hand, patients have already developed a 
Cushingoid appearance, abrupt discontinuation of MA could 
precipitate an Addisonian crisis. This can be prevented by 
supportive steroid therapy starting at a dosage of prednisone 
of 7.5 mg/day that is tapered at a rate of 2.5 mg/day every 
2–3 weeks for patients who have recently been treated with a 
course of MA and have an abnormal ACTH level. It appears 
reasonable to recommend that stress doses of prednisone be 
given during a period of acute illness or prior to surgery to 
prevent possible complications due to adrenal suppression. 
Fasting blood sugar level should be checked to monitor 
hyperglycemia or hypoglycemia.
MA nanocrystal oral suspension
The problem with MA oral suspension is its poorly solubility 
and absorption in a fasting state (Femia and Goyette 2005). 
A recent study revealed that conventional MA suspension is 
best absorbed in the fed state. Its serum concentration and effect 
is many times higher when given in a fed rather than under fast-
ing conditions (Alakhov et al 2004; Femia and Goyette 2005). 
Newer MA nanocrystal oral suspension (Megace ES) can be 
given at a dosage of 625 mg (5 mL) daily without meals.
MA oral suspension median tmax was 5 hours (Graham 
et al 1994). There was a signiﬁ  cant plasma concentration 
difference in fed versus fasting study beagle dogs (Femia 
and Goyette 2005). A signiﬁ  cant relationship was observed 
between weight gain and the percentage of the 24-hour admin-
istration interval, during which plasma concentrations of MA 
exceeded 300 ng/mL (Graham et al 1994). This may be the 
best explanation for the results in our clinical study, in which 
one third of the sickest study patients did not respond to MA 
oral suspension. These non-responders were exactly the study 
patients who were too weak and anorexic to eat and who took 
the study medication in the fasting state) (Yeh et al 2000b).International Journal of Nanomedicine 2006:1(4) 415
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MA nanocrystalline particles signiﬁ  cantly increased 
surface area per unit mass (Femia and Goyette 2005). MA 
nanocrystalline particles increase the rate of absorption and 
decrease absorption variability when the drug is taken with 
food (Alakhov et al 2004; Femia and Goyette 2005). MA 
nanocrystal oral suspension (Megace ES) can be given at a 
dosage of 625 mg (5 mL) daily without meals. Preclinical 
pharmacokinetic data suggest that the new MA formulation 
has the potential to signiﬁ  cantly shorten the time to clinical 
response and thus may improve outcomes in patients with 
anorexia–cachexia (Femia and Goyette 2005). Clinical studies 
in cancer, geriatric and HIV patients might be conducted to 
demonstrate the beneﬁ  t of the neww formulation.
Conclusion
The etiology of the wasting syndrome is multifactorial. 
Patients with documented involuntary weight loss should 
be screened for possible reversible causes and should also 
be checked for untreated hyperthyroidism, depression, poor 
dentition, uncontrolled diabetes mellitus, severe dysphagia, 
or malabsorption. They should receive aggressive nutritional 
support (food supplements [1.5–2 g/kg of protein daily, 
25–35 cal/kg daily), for a total of 2500 cal/day, dietitian 
consultations, and assistance with feeding).
If other treatable etiologies are ruled out, MA should be 
considered for use as an appetite stimulant. Because all other 
anabolic agents such as growth hormone depend on adequate 
energy intake for optimal effect, the role of nutritional support 
and appetite stimulants remains fundamental. Patients will 
typically improve their appetite within the ﬁ  rst few weeks 
after starting the drug. Weight gain, often in the form of fat, 
may take longer. Resistance exercise traing coupled with 
the weight gain may lead to improved lean muscle mass. 
A typical treatment duration may be 12 weeks. Patients 
should be monitored for signs and symptoms of adrenal 
suppression. The newer MA nanocrystal oral suspension 
(Megace ES) can be given in a smaller volume and depends 
less on a patient taking it in the fed state to achieve a clinical 
beneﬁ  t.
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